Table 6. Ratios for serum MCP-1 concentration and future CAD risk according to CCL2 haplotypes.

Haplotype	MCP-1 serum ratio (95% CI)	P*	P†	P‡	CAD risk ratio (95% CI)	P*	P†	P‡
H1	Ref	-	-	-	Ref	-	-	-
H2	0.61 (−1.25 to 2.46)	0.521	0.510	0.536	0.90 (0.77 to 1.07)	0.228	0.201	0.157
H3	1.21 (−0.70 to 3.12)	0.213	0.245	0.212	0.95 (0.80 to 1.12)	0.527	0.419	0.620
H4	−1.81 (−3.71 to 0.09)	0.062	0.045	0.065	1.06 (0.90 to 1.25)	0.481	0.638	0.438
H5	−0.23 (−2.83 to 2.36)	0.859	0.810	0.842	0.77 (0.61 to 0.98)	0.030	0.015	0.023
H6	−1.21 (−4.62 to 2.20)	0.485	0.404	0.427	0.84 (0.62 to 1.13)	0.250	0.071	0.121

Age and sex corrected MCP-1 serum concentration and future CAD risk ratios with the corresponding 95 % confidence interval for the most six common CCL2 haplotypes. The haplotype with the highest frequency (H1) is used as reference haplotype.

^*P = p value adjusted for age and sex.

^†P = p value adjusted for age and sex, waist circumference, systolic blood pressure and triglycerides;

^‡P = p value adjusted for the Framingham Risk Score.